What X9 does

X9, Inc. is a privately held medical device company founded in 2022 and incubated at ExploraMed in Mountain View, California, that is building an AI-guided point-of-care ultrasound ecosystem for minimally invasive diagnostics and procedural assistance. Its core technology combines real-time AI-powered ultrasound imaging with micro-level precision targeting procedures such as vascular access, biopsies, nerve blocks, and tumor ablations. The first commercialized product, an ultrasound-guided cannulation device intended to improve dialysis vascular access, received FDA clearance for its ultrasound-only version and completed a first-in-human feasibility study in November 2024; an enhanced power-assist version is in development. The company was launched in partnership with DaVita, a leading dialysis provider that invested through its venture group, anchoring X9's initial clinical validation and market entry into the dialysis segment. The platform is designed for interoperability with existing EMRs and hospital infrastructure, with built-in HIPAA and FDA 21 CFR Part 11 compliance architecture and a roadmap that includes predictive analytics and continuous AI health monitoring.

X9's business model centers on selling hardware devices into healthcare-provider workflows, with a broader ecosystem play encompassing software and services that support automated measurements, alerts, reporting, and reimbursement within existing payment structures. Pricing is not publicly disclosed and the company appears to use an enterprise field-sales motion targeting hospitals, dialysis providers, and multi-specialty care settings in the United States. Revenue is not yet disclosed and the company is best characterized as pre-commercial, with FDA clearance, feasibility study completion, and a December 2025 SEC Form D filing for an exempt offering of up to $33,000,708 USD (of which $8,568,181 has been sold) marking the transition from R&D toward early commercialization. Operating geographies are limited to the United States and the company remains at 1-10 employees under CEO Earl Bright.

Name

X9

Legal name

X9, Inc.

Website

https://exploramed.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

X9 is a medical device startup developing an AI-powered, point-of-care ultrasound platform with micro-precision for procedures including dialysis cannulation, vascular access, biopsies, and nerve blocks, serving healthcare providers and dialysis networks such as DaVita.

Ownership category

akta.pro rank

Product category

Interventional Ultrasound Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

Keywords

• AI ultrasound imaging
• Medical devices
• Procedural guidance
• Point-of-care diagnostics
• Dialysis cannulation

Headquarters

HQ city

Wallingford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Healthcare ecosystem platform (hardware, software, services): X9 is developing a comprehensive ecosystem including hardware devices, software platforms, and services designed for healthcare provider infrastructure. The platform supports timely, accurate reporting to facilitate reimbursement within existing payment structures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

X9 is developing a scalable, single-handed, point-of-care ultrasound platform that combines real-time AI-powered imaging with micro-level precision to guide minimally invasive procedures such as vascular access, biopsies, nerve blocks, and tumor ablations. The platform integrates hardware, software, and services designed for interoperability with existing EMRs and hospital infrastructure, and includes an FDA-cleared ultrasound-guided cannulation device targeting dialysis patients.

Product overview

X9 is developing a comprehensive healthcare technology ecosystem consisting of hardware, software, and services built around a scalable, single-handed, point-of-care ultrasound platform. The core platform integrates real-time AI-powered ultrasound imaging with micro-level precision to support healthcare providers in performing vascular access, biopsies, nerve blocks, and tumor ablations. For the dialysis market specifically, X9 has developed an FDA-cleared ultrasound-guided cannulation device with a next-generation power-assist version in development. The ecosystem also includes an AI health monitoring system that enables continuous patient monitoring and predictive analytics. The platform is designed for interoperability with existing healthcare infrastructure including EMR systems, supporting automated measurements, alerts, and reporting.

Differentiator

Problem solved

Functional benefit

Products and services

• X9 Point-of-Care Ultrasound Platform Scalable, single-handed, point-of-care ultrasound platform integrating real-time AI-powered imaging with micro-level precision to guide delicate procedures across multiple specialties and care settings. Engineered for EMR interoperability, automated measurements, alerts, predictive analytics, and HIPAA-compliant data handling for hospitals and healthcare providers.
• Ultrasound-Guided Cannulation Device FDA-cleared ultrasound-guided medical device designed to improve the cannulation process for hemodialysis patients by reducing cannulation-related complications and costs while improving patient outcomes.

Quantifiable outcome

• First-in-human feasibility study completed November

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Exo: Developer of handheld ultrasound devices with embedded AI for point-of-care imaging and procedural guidance. Direct competitor in AI-powered portable ultrasound for clinical workflows similar to X9's target use cases.
• Caption Health (acquired by GE HealthCare): AI software for real-time ultrasound guidance that automates image acquisition and diagnostic-quality assessment. Highly comparable as an AI-navigation overlay for ultrasound-based procedures, now distributed via GE HealthCare.
• Butterfly Network: Handheld, AI-enabled point-of-care ultrasound platform targeting multi-specialty and bedside use. Closest direct competitor to X9's single-handed AI-ultrasound procedural guidance model across vascular access and procedural applications.

Broad incumbents

• GE HealthCare: Global incumbent in medical imaging including ultrasound, with growing AI guidance capabilities (via Caption Health). Competes broadly across hospital imaging purchasing decisions that X9 must also win.
• Siemens Healthineers: Global ultrasound and image-guided therapy vendor with AI-augmented imaging and integrated hospital IT. Sets competitive benchmarks for AI ultrasound and image-guided procedural capabilities X9 must match or beat.
• Penumbra: Developer of interventional and procedural devices across vascular and adjacent therapy areas. Comparable as a procedural-focused medtech company expanding into image- and AI-guided therapy workflows.
• Philips: Large medical imaging incumbent offering ultrasound systems integrated with enterprise imaging/EMR workflows. Competes for hospital capital budgets and AI-imaging mindshare relevant to X9's enterprise sales motion.
• Becton, Dickinson and Company (BD) — Vascular Access: Major manufacturer of vascular access devices and ultrasound-guided cannulation tools (e.g., Site-Rite). Directly relevant to X9's anchor dialysis cannulation use case and competing procurement relationships in dialysis centers.
• Teleflex: Portfolio of vascular access, Arrow, and procedural guidance products including ultrasound-assisted cannulation devices. Comparable competitive set for X9's anchor vascular access indication.

Emerging players

• Robocath: Emerging player building robotic platforms for image-guided endovascular procedures. Comparable as a robotic procedural assistance peer whose trajectory informs adoption curves relevant to X9's power-assist roadmap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about X9